USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
EXPRESSION THERAPEUTICS
Address:
1860 Montreal Road
Tucker, GA 30084-
Phone:
N/A
URL:
N/A
EIN:
120382893
DUNS:
361719755
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,061,208.00 3
STTR Phase I $200,000.00 2
STTR Phase II $2,586,823.00 2

Award List:

High Expression Recombinant Factor VIII

Award Year / Program / Phase:
2008 / STTR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The hemophilias (A and B) are rare bleeding disorders toward which much scientific and medical effort has been devoted. In 1840, blood transfusion was used for the first time to stop post-operative bleeding in a hemophi lia patient and in 1968 the first… More

Ex Vivo Gene Therapy for Hemophilia A

Award Year / Program / Phase:
2009 / STTR / Phase II
Award Amount:
$1,126,694.00
Agency:
HHS
Principal Investigator:
Research Institution:
EMORY UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Hemophilia A is a congenital bleeding disorder caused by genetic mutations affecting a plasma protein, termed factor VIII (fVIII), whose function is to facilitate blood clotting. State of the art treatment of hemophilia A consists of frequent intravenous… More

High Expression Recombinant Factor VIII

Award Year / Program / Phase:
2010 / STTR / Phase II
Award Amount:
$1,460,129.00
Agency:
HHS
Principal Investigator:
Christopher B. Doering – 404-727-7988
Research Institution:
Emory University
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The hemophilias (A and B) are rare bleeding disorders toward which much scientific and medical effort has been devoted. In 1840, blood transfusion was used for the first time to stop post-operative bleeding in a hemophilia patient and in 1968 the first commercial… More

Development of a novel production platform for complex recombinant biotherapeutic

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$296,320.00
Agency:
HHS
Principal Investigator:
Gabriela Denning – 404-712-8554
Abstract:
DESCRIPTION (provided by applicant): The manufacturing of recombinant protein-based biopharmaceuticals is a complex, labor and capital intensive endeavor. It currently is accepted that the use of mammalian cells is a requirement for the production of mosthuman proteins, which typically contain… More

Bioengineered factor VIII gene therapy for hemophilia A

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$378,456.00
Agency:
HHS
Principal Investigator:
Gabriela Denning – 404-712-8554
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this proposal is to conduct late-stage preclinical studies to support a pilot clinical trial of hematopoietic stem cell transplantaton gene therapy for hemophilia A. In a series of recent studies, wehave shown that the transplantation of… More

Manufacturing Process Development for Bioengineered FVIII

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$386,432.00
Agency:
HHS
Principal Investigator:
Gabriela Denning – 404-712-8554
Abstract:
DESCRIPTION (provided by applicant): The manufacturing of recombinant coagulation factor VIII is a complex, labor and capital intensive endeavor. Of the recombinant proteins currently marketed, coagulation factor VIII is manufactured with the lowest efficiency and is by far the most expensive on a… More